Malignant Melanoma Clinical Trials

23 recruiting

Malignant Melanoma Trials at a Glance

23 actively recruiting trials for malignant melanoma are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Hackensack, Jerusalem, and Beijing. Lead sponsors running malignant melanoma studies include Assistance Publique - Hôpitaux de Paris, Associazione Italiana per lo Studio del Pancreas, and A.J.M. van den Eertwegh.

Browse malignant melanoma trials by phase

Treatments under study

About Malignant Melanoma Clinical Trials

Looking for clinical trials for Malignant Melanoma? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 2

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Malignant Melanoma
Merck Sharp & Dohme LLC160 enrolled38 locationsNCT06961006
Recruiting
Not Applicable

Reducing Symptom Burden Through Physical Exercise in Melanoma Patients

Malignant Melanoma
Universität Duisburg-Essen104 enrolled1 locationNCT06985056
Recruiting
Phase 1Phase 2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Phase 3

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Malignant Melanoma Stage III
Hildur Helgadottir128 enrolled3 locationsNCT06794775
Recruiting
Not Applicable

FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis

ColitisDiarrheaKidney Cancer+1 more
University of Aarhus20 enrolled1 locationNCT06206707
Recruiting
Phase 2

[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Malignant Melanoma Stage IV
Barbara Malene Fischer20 enrolled2 locationsNCT07215182
Recruiting
Phase 1Phase 2

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Malignant Melanoma
Hadassah Medical Organization50 enrolled1 locationNCT01898039
Recruiting
Phase 1

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

Solid TumorsHepatocellular Carcinoma (HCC)Malignant Melanoma+1 more
Chiome Bioscience Inc.66 enrolled5 locationsNCT06636435
Recruiting
Phase 1Phase 2

AMT-253 in Patients With Advanced Solid Tumours

Advanced Solid TumorsMalignant Melanoma
Multitude Therapeutics Inc.96 enrolled1 locationNCT06209580
Recruiting
Phase 2

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Malignant Melanoma
Royal Marsden NHS Foundation Trust16 enrolled1 locationNCT06560905
Recruiting

Video-Tumorboard PLUS

Malignant MelanomaTelemedicine
University Hospital Muenster300 enrolled3 locationsNCT06980740
Recruiting
Phase 1Phase 2

RAPA-201 Therapy of Solid Tumors

Head and Neck CancerEsophageal Squamous Cell CarcinomaSolid Tumor+6 more
Rapa Therapeutics LLC37 enrolled1 locationNCT05144698
Recruiting

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

Malignant Melanoma
Assistance Publique - Hôpitaux de Paris6,000 enrolled27 locationsNCT02828202
Recruiting
Not Applicable

A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma

Malignant Melanoma
Uppsala University1,300 enrolled20 locationsNCT03116412
Recruiting
Phase 1

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

SarcomaSCLCMalignant Melanoma+1 more
Y-mAbs Therapeutics60 enrolled8 locationsNCT05130255
Recruiting
Not Applicable

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

Gynecologic CancerMalignant Melanoma
CNAO National Center of Oncological Hadrontherapy9 enrolled1 locationNCT05478876
Recruiting
Phase 1Phase 2

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Head and Neck CancerMalignant Melanoma
GeneMedicine Co., Ltd.125 enrolled4 locationsNCT06265025
Recruiting
Phase 2

Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery

Malignant MelanomaSinonasal Melanoma
Eye & ENT Hospital of Fudan University45 enrolled1 locationNCT04879654
Recruiting
Phase 2

Melanoma Metastasized to the Brain and Steroids

Malignant Melanoma
Inge Marie Svane80 enrolled3 locationsNCT03563729
Recruiting
Phase 2

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Malignant Melanoma Stage IV
Sheba Medical Center30 enrolled1 locationNCT03166397